15 April 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Presentation at the 18^th Annual World Cancer Congress

Coiled Therapeutics plc (AIM: COIL), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, today announces that its Executive Chairman, Dr. Sotirios G. Stergiopoulos, will be a featured speaker at the 18^th Annual World Cancer Congress, taking place in Athens this week on 15 - 17 April 2026 (https://www.bitcongress.com/cancer2026/default.asp).

Dr. Stergiopoulos will deliver a presentation on 16 April 2026, titled: "Novel TACC3 Protein-Protein Interaction Inhibitor, AO-252, A Key Driver in Cancer Functions Such as DDR, Immune Evasion and CIN, Shows Potent Activity in Multiple Solid Tumors Along with Brain Metastasis."

The presentation will highlight the latest findings on the Company's lead candidate, AO-252, a first-in-class TACC3 inhibitor, and its potential to address significant unmet needs in oncology, including the treatment of brain metastases.

This presentation follows the Company's recent clinical trial update which demonstrated a superior efficacy profile and durable clinical responses for AO-252 in a heavily pre-treated patient population.

Enquiries:

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884).  Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.   The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com